ACEseq is a computational tool for allele-specific copy number estimation in tumor genomes 28 based on whole genome sequencing. In contrast to other tools it features GC-bias correction, 29 unique replication timing-bias correction and integration of structural variant (SV) breakpoints 30 for improved genome segmentation. ACEseq clearly outperforms widely used state-of-the art 31
methods, provides a fully automated estimation of tumor cell content and ploidy, and 32 additionally computes homologous recombination deficiency scores. 33
34
Copy number aberrations (CNAs) play an important role in tumorigenesis and are often used 35 to subgroup cancer entities. Whole genome sequencing (WGS) identifies CNAs at 36 unprecedented resolution, but poses challenges to CNA calling algorithms such as non-37 random errors and coverage biases 1 . Changing degrees of genomic complexity, tumor 38 heterogeneity, varying tumor cell content (TCC) and aneuploidy are further challenges when 39 analyzing tumor genomes. 40
Many modern tools combine tumor/control coverage ratios with B-allele frequencies (BAF) of 41 heterozygous SNPs 2,3 . Some tools correct for GC bias, a major source of noise in the 42 coverage signal 4 , and allow for the incorporation of SV breakpoints to assist segmentation 5 . 43
However, to the best of our knowledge, none of the available tools provides all of the above-44 mentioned features. 45
Here, we present ACEseq, a tool to estimate absolute allele-specific copy numbers on WGS 46 data. ACEseq involves coverage bias correction, genome segmentation allowing the 47 incorporation of previously known breakpoints, TCC and ploidy estimation, and absolute 48 allele-specific copy number calculation to enable fully automated CNA calling on cancer WGS 49 data without prior information requirements. 50
The first step of ACEseq performs coverage bias correction, which significantly reduces noise 51 levels ( Figure 1 ). Noisy coverage profiles as depicted in Figure 1A cause over-segmentation 52 and can mask CNAs. While GC bias correction greatly reduces noise, a remaining fluctuation 53 of the signal is still observed in the shown sample ( Figure 1B ). This fluctuation can be 54 attributed to replication timing coverage bias, which is particularly prominent in fast-replicating 55 tumors 6 (Supplementary Figure 1) . Due to cells in S-phase these samples show a higher 56 average coverage in early replicating regions than late replicating regions, as the fraction of 57 cells with already replicated DNA at early loci is higher. Correction for replication timing bias 58 further smoothens the coverage profile considerably, enabling more robust genome 59 segmentation in the next step ( Figure 1C ). Figure 1D ) indicate the magnitude of the bias. Differences in GC bias between a 64 tumor sample and its matched healthy control indicated by these quality metrics likely affect 65 sensitivity and specificity of the variant calling procedures for mutation types like insertions 66 and deletions (INDELs) and single nucleotide variants (SNVs) due to differences in coverage 1 . 67
The full width half maximum (FWHM) captures the evenness of coverage ( Figure 1E , 68 where we could show a significant correlation (n=147 germinal center derived B-cell 78 lymphomas, p-value < 0.01, Figure 1I ). 79
We often observed extremely noisy coverage profiles in matched controls from projects 80 outside the ICGC MMML-Seq, possibly due to wrong handling of blood samples, preventing 81 accurate copy number calls based on tumor/control ratios. For such samples ACEseq offers 82 an option to replace the coverage signal from the matched control with an independent 83 control whilst still maintaining the BAFs of the matched control. This control replacement 84 option enables full analysis of these sample pairs including reliable discrimination between 85 runs of homozygosity (ROH) in the germline and somatic loss of heterozygosity (LOH). 86
Furthermore ACEseq can be run without matched control enlarging the spectrum of samples 87 that can be processed. Figure 4) . 96
Additionally, genomic measures well known to be significantly associated with homologous 97 recombination (HR) defects are computed: the homologous recombination deficiency (HRD)-, 98 the large scale transition (LST) 9 -and the telomeric allelic imbalances (TAI) 10 -score. A 99 connection between these parameters and treatment response to platinum containing 100 neoadjuvants and poly-ADP-ribose polymerase (PARP) inhibition has been recently 101 affected by the presence of subclonal SNVs, it can be considered as a lower boundary for the 112 true TCC. We observed that ACEseq was able to predict the TCC with highest accuracy 113 compared to the other tools based on the number of samples deviating less than 10% from 114 Table 1) . 115
MAF-based estimates (Supplementary
Next we compared fractions of the genome with copy number gain and loss (Figure 2 ). Most 116 tools reported similar fractions of gains and losses with the exception of THetA. THetA 117 deviated strongly from the other methods in several samples, probably due to strong 118 differences in TCC estimations. TITAN and ABSOLUTE only deviated from the ACEseq 119 results in one sample each. A further investigation of these revealed that sample 4121361 120 was estimated at much higher TCC by ABSOLUTE, which requires a larger change in 121 coverage for a segment to be called as gain. The other sample (4112512), called with higher 122 fraction of gains by TITAN, was strongly affected by replication timing bias. Though ploidy and 123 TCC were estimated at similar levels, the concordance of allelic as well as total copy number 124 level was very low (Supplementary Table 2 ). TITAN and THetA showed a considerably highernumber of segments than ACEseq (factor 2-5x higher) for this particular sample, suggesting 126 that replication timing-dependent coverage bias led to oversegmentation. Resulting small 127 segments, reflecting peaks and valleys of the noisy raw coverage track, would then be 128 assigned to different copy number states. Titan and THetA increased the fraction of amplified 129 genome from less than 3 % as determined by ACEseq and ABSOLUTE to 29% and 42%, 130 respectively. No indications for this reported increased fraction were found in the raw 131 coverage data ( Figure 1A) . Furthermore, the sample's karyotype (46,X,-132 X,del(3)(p14p24),t(8;14)(q24;q32),+del (12)(q15) For a more detailed comparison we calculated the overall concordance of copy number calls 137 for both total and allele-specific copy numbers (Supplementary Table 2 THetA differed substantially from ACEseq in 7 out of 11 samples, in which THetA reported 145 much higher fractions of the genome as gained or lost. Again this is probably related to the 146 strongly deviating TCC estimates and over-segmentation. 147
Overall, these results demonstrate the good performance of ACEseq in fully automated TCC 148 and ploidy as well as allele-specific copy number estimation. ACEseq clearly benefits from its 149 unprecedented integration of many and partially new features into a single tool. Even though 150 ABSOLUTE and TITAN performed on a similar level for many of the samples they bear 151 several shortcomings. ABSOLUTE always offered multiple TCC/ploidy solutions, reaching up 152 to more than 40 possible solutions for one sample. The desired solution had to be extracted 153 manually from an R-object and required further manual interaction. TITAN resulted in very 154 good TCC estimation with the downside that the ploidy needs to be set in advance. Testing 155 different ploidies requires multiple runs per sample. Additionally a strong replication timing 156 bias caused problems for TITAN leading to over-segmentation and subsequently larger 157 fractions of segments assigned as a gain or loss.
In 
